Laronidase
CAS 210589-09-6 1 FDA-DMF supplierBiologic
Overview
Laronidase is an enzyme replacement therapy used to treat patients with mucopolysaccharidosis I (MPS I), a lysosomal storage disorder caused by the deficiency of the enzyme alpha-L-iduronidase. It works by breaking down glycosaminoglycans that build up in cells over time, alleviating symptoms associated with the disorder.
Therapeutic areas
Genetic DisordersMetabolic Disorders
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.